This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva didn’t think it could beat Gilead's HIV drug patents, companies say at US antitrust trial

By Michael Acton ( May 30, 2023, 22:27 GMT | Insight) -- Teva wasn't confident it could overcome patents for Gilead’s HIV drugs, and Teva’s own internal communications show that a 2014 settlement was its best option for bringing generic versions to market as soon as possible, lawyers for the two pharmaceutical companies told a jury in San Francisco today. Teva wasn't confident it could overcome patents for Gilead’s HIV drugs, and Teva’s own internal communications show that a 2014 settlement was its best option for bringing generic versions to market as soon as possible, lawyers for the two pharmaceutical companies told a jury in San Francisco today as the trial in the case continued....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections